PuraMatrix® has demonstrated efficacy in multiple models for hemostasis (CE Mark approved, trade name PuraStat®), tissue regeneration, acute myocardial infarction, therapeutic protein and stem cell delivery, and CNS injury. PuraMatrix® can re-hydrate and provide mechanical support for disc height collapse in degenerated IVDs, anti-adhesion, polyp resection, and bone formation. PuraMatrix® has also been used to repair and restore visual function in the CNS after damage.
The ability to stop and control bleeding is critically important to all surgical procedures and to the practice of medicine in general. Based on the self-assembling peptide platform technology of PuraMatrix®, 3-D Matrix has obtained CE mark approval for the surgical hemostatic agent PuraStat®. PuraStat® gels upon blood contact and stops bleeding (hemostasis) via mechanical blocking of the bleeding site for diffuse bleeds while allowing full, transparent view of the target area. PuraStat® has a number of unique features that distinguish it from existing products.
Click here for peer-reviewed publications of PuraMatrix® (PuraStat®) as a surgical hemostatic agent.